NCT02042989 - MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 27, 2014

Primary Completion Date

January 22, 2020

Study Completion Date

January 22, 2020

Conditions

Advanced Cancers

Interventions

DRUG

MLN9708

"Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase."

DRUG

Vorinostat

"Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston